|
65679771212eaade2e0ee298
|
2020
|
United Kingdom
|
Department of Health and Soci...al Care
more
|
2020009750
|
GAMRIF-WP2-CARB-X
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
6.034505
|
0
|
0
|
0
|
6.034505
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
GLOBAL ANTIMICROBIAL RESISTANC...E INNOVATION FUND (GAMRIF) – ACCELERATING ANTIBACTERIAL INNOVATION WITH CARB-X
more
|
Global Antimicrobial Resistanc...e Innovation Fund (GAMRIF) – Accelerating Antibacterial Innovation with CARB-X
more
|
Through the Global AMR Innovat...ion Fund (GAMRIF), the UK Department of Health and Social Care (DHSC) has invested £20 million over three years in Boston University's Combating Antibiotic Resistant Bacteria Accelerator (CARB-X), which is a non-profit, multi-donor international partnership that supports innovative early product research and development focused on the most dangerous drug-resistant bacteria. This contribution invests in high-value, innovative research to accelerate the development of products to reduce the harm from drug-resistant infections. The aim of this project is to invest in high-value, innovative research to accelerate the development of products up to and including Phase I to reduce the harm to human health, welfare and economic growth from drug-resistant infections. In particular, the programme focuses on prevention (including vaccines) and alternatives to antibiotics for humans as primarily and directly relevant to people in low- and middle-income countries (LMICs).
more
|
0
|
12250
|
Infectious disease control
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679771212eaade2e0ee299
|
2020
|
Germany
|
Foreign Office
|
2020009752
|
6615353
|
8
|
Tanzania
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.009915
|
0.009915
|
0
|
0
|
0.009915
|
0.009915
|
|
0.009915
|
|
0
|
COVID-19
|
COVID-19 Personal Protective E...quipment
more
|
100
|
FABRICATION OF FACIAL MASKS TO... PREVENT THE SPREAD OF COVID-19
more
|
Fabrication of facial masks to... prevent the spread of COVID-19
more
|
Equip hospitals with facial ma...sks to prevent the spread of COVID-19
more
|
|
12264
|
COVID-19 control
|
|
I.2.b. Basic Health
|
23000
|
Developing country-based NGO
|
Developing country-based NGO
|
|
COVID-19
|
|
65679771212eaade2e0ee29a
|
2020
|
Germany
|
Foreign Office
|
2020009753
|
6615344
|
8
|
Guinea-Bissau
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.028438
|
0.028438
|
0
|
0
|
0.028438
|
0.028438
|
|
0.028438
|
|
0
|
COVID-19
|
COVID-19 Personal Protective E...quipment
more
|
100
|
COVID-19 - PRODUCTION OF MASKS... AND DISTRIBUTION IN RURAL AREAS
more
|
Covid-19 - Production of masks... and distribution in rural areas
more
|
Covid-19 - Production of masks... and distribution in rural areas
more
|
|
12264
|
COVID-19 control
|
|
I.2.b. Basic Health
|
20000
|
Non-Governmental Organisation ...(NGO) and Civil Society
more
|
Non-governmental organisations... (NGOs) and civil society
more
|
|
COVID-19
|
|
65679771212eaade2e0ee29b
|
2020
|
Germany
|
Foreign Office
|
2020009754
|
6615355
|
1
|
Kenya
|
South of Sahara
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.0059305
|
0.005859
|
0
|
0
|
0.011861
|
0.011718
|
|
0.011861
|
|
0
|
COVID-19
|
COVID-19 Personal Protective E...quipment
more
|
50
|
MATHARE COMMUNITY COVID-19 SUP...PORT IN NAIROBI
more
|
Mathare Community Covid-19 Sup...port in Nairobi
more
|
Reducing the spread of coronav...irus in Mathare slum through improved access to masks, water and soap. Combat the effects of Covid-19 by donating water and providing zoom lessons and educational materials for students. Finally, empowerment of youth and women involved in the production of masks, soap and provision of Zoom classes.
more
|
|
12264
|
COVID-19 control
|
|
I.2.b. Basic Health
|
20000
|
Non-Governmental Organisation ...(NGO) and Civil Society
more
|
Non-governmental organisations... (NGOs) and civil society
more
|
|
COVID-19
|
|
65679771212eaade2e0ee29c
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020006643
|
GCRF_BBSRC_KEN_BB/P024270/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.218873
|
0
|
0
|
0
|
0.218873
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
THE TICK CELL BIOBANK - A UK A...ND INTERNATIONAL BIOLOGICAL RESOURCE
more
|
The Tick Cell Biobank - a UK a...nd international biological resource
more
|
Ticks are bloodfeeding arthrop...ods which, as well as causing direct damage to their hosts, transmit many diseases of livestock, companion animals and humans. Research into prevention and cure of these diseases, caused by viruses, bacteria, protozoa and filarial worms, is greatly assisted by the use of cell culture systems to study both how tick cells function, and how and why they transmit disease-causing pathogens. Such culture systems, called cell lines, have been developed for many disease-carrying ticks, but they require special skills and much time and patience to establish and maintain. Seven years ago a central collection, the Tick Cell Biobank (TCB), was created for all the tick cell lines available now and in future. The TCB distributes tick cell lines (TCL) on request to research scientists all over the world and provides essential training in their maintenance. The TCB also carries out characterisation studies on TCL, as very little is known about most of them, and is creating new cell lines from species of ticks not already represented in the collection. This proposal requests funding to secure the long-term future of the TCB as an essential resource underpinning UK and international tick and tick-borne disease research, to expand the resource to include cell lines derived from other important arthropods such as biting midges, mites and honeybees, and to give added value to the cell lines through characterisation, cloning and genome sequencing, thereby ensuring that these unique and invaluable biological resources continue to be available to the scientists who need to use them in biomedical, veterinary and agricultural research. Since the TCB was established in 2009, the crucial role played by TCL in research into ticks and the diseases they transmit has become increasingly clear. Indeed, interest in TCL and the methods used to generate them has spread to encompass pathogens transmitted by other arthropods such as mites, fleas and lice. With environmental and climate change driving the emergence of new vector-borne diseases, the demand for cell lines derived from ticks and other arthropods is likely to continue to increase in the future. This proposal includes generation of novel cell lines from ticks, mites and insects such as sand flies and midges both in-house and through dissemination of the required expertise to scientists in laboratories specialising in these arthropods. Establishment of TCL takes many years and requires specialised expertise, much patience and, importantly, a stable background of laboratory support. The TCB has brought together almost all the TCL available worldwide into a single repository and point of contact for supply of TCL and training in their maintenance (essential for successful transfer of TCL to recipient laboratories). The TCB has been enormously successful over the past 7 years, generating 18 new TCL, supplying TCL to 71 recipient laboratories and training 80 young scientists representing 27 c
more
|
0
|
43082
|
Research/scientific institutio...ns
more
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679772212eaade2e0ee29d
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007034
|
GCRF_MRC_NS_CVR
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
2.672477
|
0
|
0
|
0
|
2.672477
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
ODA PROGRAMMES WITHIN MRC CENT...RE FOR VIRUS RESEARCH
more
|
ODA Programmes within MRC Cent...re for Virus Research
more
|
The mission of the Centre for ...Virus Research is to carry out fundamental research on viruses and viral diseases, translating the knowledge gained for the improvement of health and benefit of society to multiple Lower and middle income countries
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679772212eaade2e0ee29e
|
2020
|
Germany
|
Bundesministerium für Wirtsch...aftliche Zusammenarbeit und Entwicklung
more
|
2020007010
|
201801133-3238
|
3
|
Ethiopia
|
South of Sahara
|
LDCs
|
ODA Grants
|
3
|
10
|
110
|
B01
|
0
|
0.123932
|
0
|
0
|
0
|
0.123932
|
|
0
|
|
0
|
Classified as not health-speci...fic activity
more
|
|
100
|
SEWOH - PROMOTING SUSTAINABLE ...LIVELIHOOD OF THE POPULATION THROUGH AGRO-ECOLOGY MEASURES, NUTRITION PROGRAMMES AND WATER SUPPLY IN SIX COMMUNITIES
more
|
SEWOH - Promoting sustainable ...livelihood of the population through agro-ecology measures, nutrition programmes and water supply in six communities
more
|
SEWOH - Promoting sustainable ...livelihood of the population through agro-ecology measures, nutrition programmes and water supply in six communities
more
|
|
12240
|
Basic nutrition
|
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think-tank
more
|
|
|
|
65679772212eaade2e0ee29f
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020006996
|
GCRF_MRC_NS_MR/P010288/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.016461
|
0
|
0
|
0
|
0.016461
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MEMBRANE AND HOST CYTOSKELETON... REORGANIZATION DURING MALARIA PARASITE EGRESS FROM ERYTHROCYTES
more
|
Membrane and host cytoskeleton... reorganization during malaria parasite egress from erythrocytes
more
|
Malaria is a major global kill...er, most deadly for children in the developing world. Of the five species that infect humans, Plasmodium falciparum is the most lethal. Although there are currently effective anti malarial drugs, the appearance and spread of resistant strains of P falciparum pose an increasing threat. The parasite has a complex life cycle with several different stages in its mosquito and human hosts, but the clinical symptoms in humans arise from waves of parasite release during the asexual blood stages, in which parasites invade red blood cells and multiply within an internal membrane compartment called a vacuole. The growing parasites hijack their host blood cells, consume their haemoglobin, and redirect the cell activity for the benefit of the parasite. Of particular importance, the parasite exports some of its own proteins to build new structures on the surface of the blood cell. A uniquely lethal aspect of P. falciparum is that it creates surface protrusions (called knobs) on the blood cell that make it adhere to the lining of blood vasculature. This prevents the infected cells from being captured and destroyed by the spleen, but can also block brain blood capillaries, the main cause of death in malaria infection. Once they have matured, 16-24 daughter parasites break through their surrounding vacuole membrane as well as the red blood cell membrane (a process collectively called egress) to enter the bloodstream, where they immediately invade a fresh round of blood cells. The processes of invasion, adhesion and egress are regulated through a cascade of enzyme reactions, as well as expression and transport of structural components. Some of these components are unique to malaria, making them potential targets for future drug development. Currently, most of them are poorly characterised. In this project, we focus on the steps by which the mature parasites break through the two bounding membranes to undergo egress. A highly regulated series of steps leads to the explosive release of parasites from the blood cell. To examine these membrane breakage events in detail, we use electron microscopy to image at nanoscale resolution the three-dimensional structures of the infected cells during the late stages of parasite development. This imaging is combined with use of parasite mutants and drug-like molecules and enzyme inhibitors to trap the parasites at different steps of egress. This approach has already led us to discover a new, initial step in egress that had not been previously detected. We now know that the process begins with the parasites causing the membrane surrounding their vacuole to become leaky. Subsequently, this membrane is completely disrupted, allowing the parasites to move freely inside the blood cell. Shortly after that, the blood cell membrane itself becomes leaky and then finally the cell membrane and its underlying cytoskeleton rupture to allow the parasites to escape and invade new host blood cells. With recent adva
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679772212eaade2e0ee2a0
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007008
|
GCRF_MRC_NS_MR/P011128/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.06567
|
0
|
0
|
0
|
0.06567
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
VACCINE: DEVELOPMENT AND EVALU...ATION OF VECTORED VACCINES FOR HCV USING AN ENHANCED GENE EXPRESSION TECHNOLOGY IN A NOVEL RODENT HEPACIVIRUS MODEL
more
|
VACCINE: Development and evalu...ation of vectored vaccines for HCV using an enhanced gene expression technology in a novel rodent hepacivirus model
more
|
Hepatitis C virus (HCV) is a m...ajor pathogen worldwide, causing progressive and often severe liver disease in the estimated 160 million people infected with the virus. In the UK, a substantial proportion of the estimated 350,000 individuals chronically infected with HCV will eventually develop cirrhosis and liver cancer (hepatocellular carcinoma, HCC) if left untreated. While there is treatment available, conventional therapies based on interferon are effective in only a proportion of those treated while more recently developed antiviral therapy that directly targets the virus is expensive and its use will remain cost-limited for many years. Importantly, such treatments will not stem the spread of HCV and the large numbers of new infections recorded every year, even those who have been effectively treated remain prone to re-infection. HCV also poses a much greater medical problem worldwide where access to treatment will remain limited in much the same as HIV therapy. HCV-related deaths worldwide exceed 350,000 per year, of the same order to those attributed to AIDS, TB and malaria. Large scale immunisation with a safe and effective HCV vaccine would induce life-long immunity to HCV and prevent further spread of the virus to those currently at risk for infection. Secondly, the therapeutic use of a vaccine in which immunisation would control and clear infection in those already infected with HCV would prevent and in many cases reverse development of liver disease complications, such as cirrhosis and HCC associated with long term chronic infection. The development of such vaccines would therefore have profound effects on global health. The development of HCV vaccine has been hampered by a lack of animal models with which to test different type of vaccine. It has also proven exceptionally difficult to develop vaccines that induce long-lived protective immunity - even clearance of natural infections does not protect from subsequent re-infection, quite unlike the situation of poliovirus, measles and hepatitis A virus (as examples) for which effective vaccines have been developed. We believe the solution to the problems is to generate novel vaccines in which viral proteins, such as those from HCV, are inserted into another virus, cytomegalovirus (CMV) or adenovirus (AdV). A feature of CMV infections is that although harmless, infection leads invariably to persistent infections. Infections with CMV containing inserted HCV genes, once established, would therefore continuously immunise the body against HCV, much more so than infection with HCV itself. The most compelling evidence for the effectiveness of this method of immunisation arises from HIV vaccine research, where CMV vectors were effective at preventing infection of macaques with SIV, a monkey version of HIV. Furthermore, the CMV/SIV vaccine was able to clear infection from macaques already infected with SIV. A human version of this CMV vaccine, containing HIV genes, is currently entering huma
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679773212eaade2e0ee2a1
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007011
|
GCRF_MRC_NS_MR/P021611/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.145041
|
0
|
0
|
0
|
0.145041
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MOLECULAR MECHANISMS OF SPOROG...ONIC DEVELOPMENT IN MALARIA PARASITES
more
|
Molecular mechanisms of sporog...onic development in malaria parasites
more
|
New therapies for prevention a...nd treatment of malaria, and for reducing transmission, are urgently needed. This project aims to increase our understanding of the molecular mechanisms underlying the formation and function of the crystalloid - a malaria parasite organelle found uniquely in the ookinete and young oocyst stages that is essential for sporogonic development and sporozoite transmission from mosquito to human. A palmitoyl-S-acyl transferase enzyme named DHHC10 resides in the crystalloid and is essential for crystalloid formation and parasite transmission. DHHC10 catalyses the addition of a palmitoyl lipid to proteins, a reaction known as palmitoylation. This project will focus on the role of palmitoylation in crystalloid biogenesis and function. Using the Plasmodium berghei mouse malaria model, we will determine the substrate range, spatiotemporal dynamics and mechanisms of DHHC10-mediated palmitoylation in crystalloids via three specific objectives: Objective 1: Determine the crystalloid palmitome. Using a method called acyl-biotin-exchange (ABE) the palmitoyls on palmitoylated proteins are chemically exchanged for biotin, which allows their specific capture and purification with microbeads that bind biotin. Following this, the palmitoylated protein fraction (palmitome) is analyzed by mass spectrometry (MS) to determine the identities of the individual protein components. By comparing the palmitomes from ookinetes that express DHHC10 and those that do not (DHHC10-knockouts), the substrates of DHHC10 can be identified, which correspond to the crystalloid palmitome. In parallel, the ookinete palmitome of a DHHC-positive, but crystalloid-negative, parasite line (LAP3-knockout) will be determined to study the spatiotemporal dynamics of DHHC10-mediated palmitoylation. The results will provide a global view of the palmitoylated protein repertoire in the whole ookinete and in the crystalloid, and will identify new crystalloid components. Objective 2: Identify proteins that interact with DHHC10. Proteins that interact with DHHC10 (either subunits of a DHHC10 protein complex, or DHHC10 substrates) will be identified by two approaches. (i) GFP pull-down: ookinetes that express DHHC10 fused to green fluorescent protein (GFP) will be used to capture DHHC10 protein complexes using magnetic beads that can bind to the GFP, and these complexes will then be analyzed by MS to determine their protein composition. (ii) BioID: ookinetes that express DHHC10 fused to a biotin ligase (BirA*) can be used to specifically biotinylate DHHC10 and its neighbour proteins upon addition of excess biotin to the cells. This allows their specific capture with magnetic beads that bind to biotin, followed by MS analysis. BioID analysis of ookinetes expressing a different crystalloid protein (LAP3) fused to BirA* will be carried out to validate the DHHC10 results. The results will identify new protein partners and substrates of DHHC10, as well as new crystalloid component
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679773212eaade2e0ee2a2
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007004
|
GCRF_MRC_NS_MR/P02260X/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.03975
|
0
|
0
|
0
|
0.03975
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
STRUCTURAL BIOLOGY OF IMMUNE R...ECEPTORS IN DISEASE-CARRYING MOSQUITOES
more
|
Structural biology of immune r...eceptors in disease-carrying mosquitoes
more
|
Mosquitoes are among the deadl...iest insects as they are reservoirs of pathogenic organisms that cause life-threatening diseases including malaria, yellow and dengue fever among others. These diseases are transmitted from host to host by the mosquito during their blood meal. It has been reported that an infectious mosquito has an increased appetite, which boosts the transmission efficiency of the germs. It is currently not clear how the mosquito deals with the infection and how the germs bypass the mosquito's immune system. What is known so far comes mostly from the study of the fruit fly Drosophila melanogaster that serves as a model organism for insects. Considerable insight has been gained from this system and led to the discovery of key signalling pathways in innate immunity conserved throughout the animal kingdom. The TOLL pathway is of particular interest to me as it combines functions during development and adult life, in the immune and nervous systems. This makes the TOLL pathway a multifaceted target for intervention. My main objective is to characterize the mechanism of TOLL activation and signalling in mosquitoes. Members of the TOLL family are membrane proteins with an extracellular region responsible for ligand recognition, a single-spanning transmembrane region and an intracellular domain able to transmit the signal inside the cell. The cell, in turn, produces antimicrobial peptides and coordinates different cellular processes in order to mount the appropriate immune reaction against the infection. My first aim is to characterize the three-dimensional structures of mosquito TOLL receptors providing size, shape and charge information. The second aim is to characterize the complex formed with their ligand to reveal their mechanism of activation. Both aims will be tackled using computational approaches of protein modelling, based on their common ancestry with Drosophila TOLL1, whose structure is known in the absence and presence of its ligand Spatzle 1 (SPZ1). SPZ1 is a signalling molecule that belongs to the same family of proteins as mammalians neurotrophins (NTs), which have recently been involved in physiological mechanisms regulating food intake, as well as vertebrate innate immunity. The recognition mechanism of Drosophila SPZ by TOLL is governed by shape and electrostatic complementary, as well as spatial restriction due to 'sugar-coating' at the surface of the receptor. Predictive docking of mosquito complexes relies on coevolution at protein interfaces. These predictions will be verified experimentally using biophysical techniques, X-ray crystallography and cryo-electron microscopy for atomic structure determination and cell-based functional studies, such as mutagenesis, reporter gene assays and fluorescence microscopy. Cellular signalling assays will be based on transiently transfected cells stimulated by SPZ and NT isoforms or microbial signature molecules, as appropriate, in order to trigger cellular responses in the form
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679773212eaade2e0ee2a3
|
2020
|
Switzerland
|
Swiss Agency for Development a...nd Co-operation
more
|
2020007014
|
177-Q37-2020-91534
|
3
|
India
|
South & Central Asia
|
LMICs
|
ODA Grants
|
7
|
10
|
110
|
B01
|
0
|
0.106043
|
0
|
0
|
|
0.106043
|
|
|
|
|
COVID-19
|
COVID-19 General
|
100
|
IN COVID 19 RÉPONSE
|
IN Covid 19 Réponse
|
The SDC negotiates programme c...ontributions as part of institutional partnerships. For the assessment and negotiation of programme contributions, which is based on the NGO's overall programme, the organisation is required to have a long-standing track record and have successfully undergone the admission procedure. Programme contributions are an investment in the competences and capacities of the NGOs and in the relevance of their programmes.
more
|
|
72010
|
Material relief assistance and... services
more
|
8,6,5,3,2,16,11,10,1
|
VIII.1. Emergency Response
|
22000
|
Donor country-based NGO
|
Fondation Terre des Hommes (La...usanne)
more
|
|
COVID-19
|
|
65679773212eaade2e0ee2a4
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007025
|
GCRF_MRC_NS_MR/R005974/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.658013
|
0
|
0
|
0
|
0.658013
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
BACTIVAC
|
BactiVac
|
Vaccines save millions of live...s every year and typically work silently in the background, promoting the body's ability to kill the pathogen before an infection is established. Despite this, bacteria still cause around six millions deaths/year in humans and many more in animals, with people in low and middle-income countries (LMICs) disproportionately affected. Worryingly, as anti-microbial resistance (AMR) increases, the number of deaths from infection will rise with devastating personal and economic consequences. One reason bacteria can cause so much harm is because there are many different diseases caused by bacteria for which there is either no vaccine or the existing vaccine does not provide complete protection. New vaccines against bacterial infections will help people in all countries, but most prominently in LMICs. Unfortunately, there are many barriers that currently prevent such vaccines from being developed. These barriers can be for scientific reasons, such as what to put in the vaccine, or economic issues, such as neglect due to lack of commercial viability. To help overcome these barriers and deliver new vaccines to where they are needed, a network is needed that enables scientists, clinicians and companies from around the world to come together and share their skills and knowledge. This is what the 'BactiVac' bacterial vaccinology network for human and animal vaccines will achieve. The network will be centred in the UK, harnessing the considerable strength already present in the UK in disciplines related to bacterial vaccinology, including immunology, epidemiology, systems biology, clinical trials and support for vaccine licensure. Crucially, the network will build on and foster new partnerships with LMICs, with industry, and manufacturers in developing countries. BactiVac will support bacterial vaccine development from when the idea is conceived to when it is licensed for use in humans or animals, particularly helping at those points where most potential vaccines flounder. The network will achieve these ambitions by combining a number of approaches. 1. The network will identify which diseases in LMICs caused by bacteria should be prioritised and how the broad vaccine community can be helped to make new vaccines that prevent them. 2. We will provide training grants, particularly for members from LMICs, to learn the skills needed to grow the research and industrial base in vaccinology. 3. By interconnecting the diverse experience and skills within the membership, we will facilitate new partnerships and sharing of information, supported by the creation of a member directory, a BactiVac website and regular newsfeeds, along with an annual networking meeting. 4. To encourage these new partnerships, the network will support small scale 'catalyst' projects through an open annual competition. These projects will grow new areas and partnerships to encourage larger scale funding, accelerate vaccine development and to help overcome th
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679773212eaade2e0ee2a5
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007026
|
GCRF_MRC_NS_MR/R005982/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.659759
|
0
|
0
|
0
|
0.659759
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
HUMAN INFECTION CHALLENGE VACC...INE (HIC-VAC) NETWORK
more
|
Human infection challenge vacc...ine (HIC-vac) network
more
|
Although vaccines save million...s of lives around the globe every year, there are many infectious diseases that still kill large numbers of people that are still not preventable by vaccination. This is especially true in low and middle income countries (LMIC) where even basic hospital treatment is unavailable, and the only realistic option is to prevent infectious diseases by finding new and economically viable vaccines. For several hundred years the UK has led the world in making original scientific discoveries by human experimentation. Although there are clearly risks in infecting people with pathogens, these risks need to be balanced against the great advantage of being able to test vaccines experimentally without waiting for people to acquire infections naturally. Central to our network is a close collaboration with scientists in these LMIC to advocate for the value of these studies with regulators, policy makers and the public and then to support scientists to perform the studies. Developing a new vaccine typically takes 20 years and costs over £1bn. Using experimental challenge studies, definitive results can be obtained showing that a vaccine works or does not work with only a few volunteers - perhaps 10 to 100. Conducting challenge studies in this way allows proof in principle of vaccine efficacy. By contrast, field studies that are needed to prove that a vaccine works can be vast, usually involving thousands of individuals and costing many times more than a human challenge study. Ethically, the benefits of human challenge need to be weighed carefully against the intention to cause disease. This narrows the range of infections that can be tested to those where the disease is relatively mild or predictable and self-limiting, or diseases that can be easily and reliably treated by existing drugs or supportive care. Examples of human infection studies that are on-going in the United Kingdom include influenza, RSV, rhinovirus, typhoid, malaria, bacterial pneumonia and whooping cough. Although there are problems to be overcome, vaccine development for emerging viruses such as Zika, dengue and MERS would be greatly accelerated if human challenge could be performed. The field of vaccines is entering a very exciting stage in that many immunological concepts that have emerged from studies in animals are now ready for testing in man. At present the groups around the UK, in London, Oxford, Liverpool, York, Nottingham and Southampton, face the ethical and regulatory challenges to mounting such studies without a structure to provide mutual support. We have a great deal to learn from one another regarding not only experimental techniques but also how to overcome the large but necessary burden of regulation and safe working practices. There are groups working on similar infections but not sharing reagents, tested pathogens or other resources between them. Our proposed network will bring together all of this expertise, build on the support that we have f
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679773212eaade2e0ee2a6
|
2020
|
Switzerland
|
Swiss Agency for Development a...nd Co-operation
more
|
2020007030
|
177-Q37-2020-92662
|
3
|
Sudan
|
South of Sahara
|
LDCs
|
ODA Grants
|
7
|
10
|
110
|
B01
|
0
|
1.141032
|
0
|
0
|
|
1.141032
|
|
|
|
|
COVID-19
|
COVID-19 General
|
100
|
COVID19-KHARTOUM
|
COVID19-Khartoum
|
The SDC negotiates programme c...ontributions as part of institutional partnerships. For the assessment and negotiation of programme contributions, which is based on the NGO's overall programme, the organisation is required to have a long-standing track record and have successfully undergone the admission procedure. Programme contributions are an investment in the competences and capacities of the NGOs and in the relevance of their programmes.
more
|
|
12220
|
Basic health care
|
6,5,3,2,17,16,10
|
I.2.b. Basic Health
|
22000
|
Donor country-based NGO
|
Médecins Sans Frontières Sui...sse
more
|
|
COVID-19
|
|
65679773212eaade2e0ee2a7
|
2020
|
Germany
|
Bundesministerium für Wirtsch...aftliche Zusammenarbeit und Entwicklung
more
|
2020007018
|
201801133-3669
|
3
|
Somalia
|
South of Sahara
|
LDCs
|
ODA Grants
|
3
|
10
|
110
|
B01
|
0
|
0.382708
|
0
|
0
|
0
|
0.382708
|
|
0
|
|
0
|
Classified as not health-speci...fic activity
more
|
|
100
|
THE PROJECT CONTRIBUTES TO THE... REDUCTION OF HUNGER AND INCREASED RESILIENCE OF THE POPULATION OF THE HIRAAN REGION IN SOMALIA.
more
|
The project contributes to the... reduction of hunger and increased resilience of the population of the Hiraan region in Somalia.
more
|
The project contributes to the... reduction of hunger and increased resilience of the population of the Hiraan region in Somalia.
more
|
|
12240
|
Basic nutrition
|
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think-tank
more
|
|
|
|
65679774212eaade2e0ee2a8
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007023
|
GCRF_MRC_NS_MR/S00467X/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.403479
|
0
|
0
|
0
|
0.403479
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MICA: NEW COMBINATION THERAPY ...AGAINST MDR TB TARGETING THE RESPIRATORY CHAIN
more
|
MICA: New combination therapy ...against MDR TB targeting the respiratory chain
more
|
Tuberculosis (TB) is the main ...cause of deaths related to antimicrobial resistance. In 2016, there were an estimated 10.4 million new TB cases worldwide, and 1.7 million TB-associated deaths. Multi -drug-resistant (MDR) TB is on the rise and globally, the average cure rate for MDR-TB is only 54% and only 30% for extensively drug resistant TB (XDR-TB). TB is a disease of poverty and presently, 95 % of the TB-related deaths occur in LMICs. The proposed activities are primarily and directly relevant to the health needs of LMIC and therefore ODA compliant New combination therapies that can overcome current resistance mechanisms are urgently required. Here, we wish to validate an exciting new therapeutic approach of targeting multiple respiratory chain components of Mycobacterium tuberculosis, the causative pathogen of TB. The co-investigators, assembled from both academia and the pharmaceutical industry, are uniquely placed to exploit this strategy possessing (i) extensive domain expertise, (ii) proprietary compound libraries containing selective inhibitors of 4 key respiratory chain components, (iii) access to validated in vitro and in vivo models for assessment of efficacy for drug combinations and (iv) background intellectual property (IP) to both inhibitors and the combinatorial approach. Our objective is to gain validation of this approach using gold-standard in vitro and vivo disease models of TB and to identify the combination of targets eliciting the optimal antitubercular effect which are most likely to be of value in the clinic. In addition, we will also investigate the potential of inhibitor combinations, in reducing the emergence of new drug resistance, thus potentially extending the lifetime of any new therapeutic solution. The resulting information will inform and aid in prioritization of drug discovery and development programs that aim to identify inhibitors of respiratory chain components that, when used together, should contribute sterilizing activity to novel drug regimens for MDR-TB, resulting in shorter treatment times for patients. Ongoing discovery programs that will directly benefit from the research output include our own and those of our industrial partner, in addition, we expect the data generated to inspire additional TB discovery and development programs in the wider TB community.
more
|
0
|
12182
|
Medical research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679774212eaade2e0ee2a9
|
2020
|
Germany
|
Foreign Office
|
2020008425
|
6611326
|
3
|
Yemen
|
Middle East
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
2.5641025
|
1.994302
|
0
|
0
|
10.25641
|
7.977208
|
|
10.25641
|
|
0
|
Emergency projects (meeting ad...ditional funding needs)
more
|
|
25
|
RELIEF AND PROTECTIVE MEASURES... YEMEN
more
|
Relief and protective measures... Yemen
more
|
Protective measures, health an...d water supplies, and physical rehabilitation for conflict-affected people in Yemen
more
|
0
|
72010
|
Material relief assistance and... services
more
|
|
VIII.1. Emergency Response
|
21016
|
International Committee of the... Red Cross
more
|
International Committee of the... Red Cross (ICRC)
more
|
|
|
|
65679774212eaade2e0ee2aa
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008419
|
MRC_NS_LEU
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.387328
|
0
|
0
|
0
|
0.387328
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
ODA PROGRAMMES WITHIN MRC LIFE...COURSE EPIDEMIOLOGY UNIT
more
|
ODA Programmes within MRC Life...course Epidemiology Unit
more
|
ODA Programmes within MRC Life...course Epidemiology Unit
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679774212eaade2e0ee2ab
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008411
|
MRC_NS_MR/M011569/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.148568
|
0
|
0
|
0
|
0.148568
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
EXPERIMENTAL HUMAN PNEUMOCOCCA...L CARRIAGE TO DETERMINE OPTIMAL PROTECTION FROM CARRIAGE AND MECHANISMS OF MUCOSAL IMMUNISATION AGAINST DISEASE
more
|
Experimental Human Pneumococca...l Carriage to determine optimal protection from carriage and mechanisms of mucosal immunisation against disease
more
|
MRC IIB award - Experimental H...uman Pneumococcal Carriage to determine optimal protection from carriage and mechanisms of mucosal immunisation against disease
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679774212eaade2e0ee2ac
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008406
|
MRC_NS_MR/M021157/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.066839
|
0
|
0
|
0
|
0.066839
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
DISSECTING THE RED BLOOD CELL ...INVASION PATHWAYS OF THE MALARIA PARASITE PLASMODIUM KNOWLESI
more
|
Dissecting the Red Blood Cell ...Invasion Pathways of the Malaria Parasite Plasmodium knowlesi
more
|
MRC CDA Fellowship award - Dis...secting the Red Blood Cell Invasion Pathways of the Malaria Parasite Plasmodium knowlesi
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679774212eaade2e0ee2ad
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008402
|
MRC_NS_MR/N002091/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.040684
|
0.000804
|
0
|
0
|
0.040684
|
0.000804
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
IMMUNOLOGICAL RESPONSES TO EME...RGING PHLEBO- AND ARENAVIRUSES
more
|
Immunological responses to eme...rging phlebo- and arenaviruses
more
|
MRC IIB award - Immunological ...responses to emerging phlebo- and arenaviruses
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679775212eaade2e0ee2ae
|
2020
|
Germany
|
Foreign Office
|
2020008400
|
6610847
|
8
|
Myanmar
|
South & Central Asia
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.2849
|
0.2849
|
0
|
0
|
0.2849
|
0.2849
|
|
0.2849
|
|
0
|
Emergency projects (meeting ad...ditional funding needs)
more
|
|
100
|
BASIC MEDICAL CARE
|
Basic medical care
|
Implementation of basic medica...l services, improvement of acute malnutrition and emergency assistance for people affected by the conflict
more
|
0
|
72010
|
Material relief assistance and... services
more
|
|
VIII.1. Emergency Response
|
22000
|
Donor country-based NGO
|
Donor country-based NGO
|
|
|
|
65679775212eaade2e0ee2af
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008413
|
MRC_NS_MR/R010307/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.216199
|
0
|
0
|
0
|
0.216199
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
HARNESSING THE STRUCTURAL FLEX...IBILITY OF BOVINE MONOCLONAL ANTIBODIES FOR THE TREATMENT OF EMERGING VIRUS INFECTIONS
more
|
Harnessing the structural flex...ibility of bovine monoclonal antibodies for the treatment of emerging virus infections
more
|
MRC IIB award - Harnessing the... structural flexibility of bovine monoclonal antibodies for the treatment of emerging virus infections
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679775212eaade2e0ee2b0
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008416
|
MRC_NS_MR/T001267/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.271492
|
0
|
0
|
0
|
0.271492
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
INDOOR BEHAVIOUR MAPS TO GUIDE... ARBOVIRUS VECTOR CONTROL
more
|
Indoor behaviour maps to guide... arbovirus vector control
more
|
MRC IIB grant RM19 aiming to u...se video tracking technology, developed by theapplicants, to map the resting and flight patterns of Ae. aegypti within an experimental 'simulated home' environment, to identify key locations within the human home where this difficult vector can be targeted rapidly, effectively and safely.
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679775212eaade2e0ee2b1
|
2020
|
Germany
|
Foreign Office
|
2020009779
|
6615406
|
8
|
South Sudan
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0.003926
|
0.003926
|
0
|
0
|
0.003926
|
0.003926
|
|
0.003926
|
|
0
|
Other health problems
|
Mental health
|
100
|
EMPOWERING STREET CHILDREN ON ...LIFE SKILL (SUPER CHARCOAL LIGHTER) TRAINING AND PRODUCTION
more
|
Empowering street children on ...life skill (Super Charcoal Lighter) training and production
more
|
To support and build the capac...ity, hope and confidence of vulnerable children towards reduction of child's protection concerns (violence) impacted by external factors and individual personalities/or behavior and other unbearable circumstance. Inspire the lives of children in need to attain basic care support and life skill, knowledge intervention through means of engaging them in income generating activities. To engage young children with protection concerns in decision making and social activities such as functional events, radio talk show programs, that will build confidence in them and relieve them from psychosocial distress.
more
|
|
12340
|
Promotion of mental health and... well-being
more
|
|
I.2.c. Non-communicable diseas...es (NCDs)
more
|
23000
|
Developing country-based NGO
|
Developing country-based NGO
|
|
|
|
65679775212eaade2e0ee2b2
|
2020
|
United Kingdom
|
Department of Health and Soci...al Care
more
|
2020009778b
|
UKVN-CVD-IUK
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
5.853393
|
0
|
0
|
0
|
5.853393
|
0
|
0
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
UK VACCINE NETWORK - CLINICAL ...VACCINE DEVELOPMENT COMPETITION
more
|
UK Vaccine Network - Clinical ...Vaccine Development Competition
more
|
This £35m competition support...s the development of new vaccines and vaccine technologies to combat diseases with epidemic potential in low and middle income countries (LMICs). It does this through supporting the clinical development of candidate vaccines and vaccine platform technologies which aim to tackle diseases of epidemic potential LMICs, ultimately to support an effective and rapid response during future outbreaks of disease in LMICs. This competition funds seven projects, which research a Chikungunya vaccine, an Ebola vaccine, a Zika Vaccine, a Nipah vaccine to eliminate porcine reservoirs and safeguard human health, a vaccine against mosquito borne diseases, a Zika and Chikungunya vaccine, and a Plague vaccine. This competition is run through Innovate UK.
more
|
0
|
12250
|
Infectious disease control
|
|
|
11001
|
Central Government
|
Central Government
|
|
|
|
65679775212eaade2e0ee2b3
|
2020
|
United Kingdom
|
Department of Health and Soci...al Care
more
|
2020009774b
|
UKVN-EFV-CCF
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
1.747719
|
0
|
0
|
0
|
1.747719
|
0
|
0
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
UK VACCINE NETWORK - EPIDEMIOL...OGY FOR VACCINOLOGY COMPETITION
more
|
UK Vaccine Network - Epidemiol...ogy for Vaccinology Competition
more
|
This £5 million competition s...upports the development of new vaccines and vaccine technologies to combat diseases with epidemic potential in low and middle income countries (LMICs). It does this through supporting five projects seeking to develop epidemiological models, tools and technologies to assist with the deployment and clinical trialling of vaccines in outbreak situations LMICs on the Development Assistance Committee (DAC) list. This competition funds the optimal Deployment of Vaccines in Outbreak Situations, in which one project has been awarded £1.5m to develop rigorous models for how priority diseases could spread in an outbreak setting. This competition also funds the development of other tools, technologies and methodologies to assist epidemiological work in outbreak settings. Under this section four projects have been awarded a total of £2.7m and include work such as an electronic data kit to support epidemiological research in LMICs during epidemics and anthropological work exploring vaccine deployment in LMICs during an epidemic.This competition is run through the National Institute of Health Research's Central Commissioning Facility.
more
|
0
|
12250
|
Infectious disease control
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679775212eaade2e0ee2b4
|
2020
|
Germany
|
Foreign Office
|
2020009781
|
6615412
|
8
|
Congo
|
South of Sahara
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.008907
|
0.008907
|
0
|
0
|
0.008907
|
0.008907
|
|
0.008907
|
|
0
|
COVID-19
|
COVID-19 Personal Protective E...quipment
more
|
100
|
COVID-19 -PRODUCTION/PURCHASE ...OF COMMUNITY MASKS
more
|
Covid-19 -production/purchase ...of community masks
more
|
Interruption of corona virus s...preading
more
|
|
12264
|
COVID-19 control
|
|
I.2.b. Basic Health
|
62000
|
Private sector in recipient co...untry
more
|
Private sector in recipient co...untry
more
|
|
COVID-19
|
|
65679776212eaade2e0ee2b5
|
2020
|
Germany
|
Foreign Office
|
2020009782
|
6615410
|
8
|
Pakistan
|
South & Central Asia
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.0081235
|
0.0081235
|
0
|
0
|
0.016247
|
0.016247
|
|
0.016247
|
|
0
|
COVID-19
|
COVID-19 General
|
50
|
COVID-19 PANDEMIC EMERGENCY HE...LP TO MARGINALIZED STUDENTS IN THE DIOCESE OF FAISALABAD, PAKISTAN
more
|
Covid-19 Pandemic Emergency He...lp to Marginalized Students in the Diocese of Faisalabad, Pakistan
more
|
The Diocese Faisalabad runs se...veral schools and tries to equally support Christian and Muslim school children from marginalized families. ichen und muslimischen Kindern aus The projcts intends to - dress up 300 poor, needy children with winter clothes, provide them with school materials, - inform them about Covid19 prevention and provide psychosocial support, - offer classes about hygiene, - public awareness campaign about Covid19 and hygiene
more
|
|
12264
|
COVID-19 control
|
|
I.2.b. Basic Health
|
23000
|
Developing country-based NGO
|
Developing country-based NGO
|
|
COVID-19
|
|
65679776212eaade2e0ee2b6
|
2020
|
United Kingdom
|
Department of Health and Soci...al Care
more
|
2020009773b
|
UKVN-PVD-IUK
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
2.518056
|
0
|
0
|
0
|
2.518056
|
0
|
0
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
UK VACCINE NETWORK - PRECLINIC...AL VACCINE DEVELOPMENT COMPETITION
more
|
UK Vaccine Network - Preclinic...al Vaccine Development Competition
more
|
This £24,719,293 competition ...supports the development of new vaccines and vaccine technologies to combat diseases with epidemic potential in low and middle income countries (LMICs). It does this through supporting the preclinical development of candidate vaccines and vaccine platform technologies. This competition is run through Innovate UK.This competition has an initial funding stage, after which successful projects could apply for follow on funding to support continued development of their vaccine products. This includes early stage clinical work. Twenty two projects were supported through the first phase of the competition and seven progressed to the second stage funding. These projects include research for a Ebola Lassa Marburg vaccine, advancing a Hantavirus vaccine, a Q fever vaccine, two haemorrhagic fever vaccine projects, serological vaccine standards research, and a Crimean Congo Haemorrhagic Fever vaccine.
more
|
0
|
12250
|
Infectious disease control
|
|
|
11001
|
Central Government
|
Central Government
|
|
|
|
65679776212eaade2e0ee2b7
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007007
|
GCRF_MRC_BRZ_MR/V033530/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.060374
|
0
|
0
|
0
|
0.060374
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
DETERMINING THE PERSISTER POPU...LATIONS IN SPUTUM DURING TUBERCULOSIS THERAPY. A SUPPLEMENTARY STUDY TO THE RIFASHORT TRIAL.
more
|
Determining the persister popu...lations in sputum during tuberculosis therapy. A supplementary study to the RIFASHORT trial.
more
|
Nearly ten million people deve...loped TB in 2014 and 1.5 million died. Although drug resistance is a serious problem, the vast majority of infections are treatable with standard antibiotics effective against the TB bacterium, known as Mtb, which causes this devastating disease. Treatment of TB currently requires patients to take antibiotics for 6 months. Even after this the disease returns in up to 5% of individuals, usually within a year after stopping therapy. Developing treatments with shorter duration and lower disease return (or relapse) rates is a major goal of global TB control efforts. Testing new treatments is very expensive, requires hundreds of patients and takes many years. Our project aims to reduce these barriers to testing and enable shortened treatment. The need for prolonged therapy and the frequency of relapse are thought to be due to significant numbers of Mtb bacteria in an altered state that survive exposure to antibiotics, the altered bacteria are known as persisters. While growing cells of Mtb are rapidly killed in conventional lab tests, cells in the non-growing persister state are not. Our team has been studying the persister phenomenon in TB for many years. In the past decade we discovered features of Mtb in the sputum (coughed up phlegm) of newly diagnosed patients that, surprisingly, indicated the presence of non-growing persisters amongst the bacteria that clinical labs normally isolate. These features are recognised in 3 ways, microscopy to detect fatty droplets inside the Mtb cells, lab culture in the presence of a growth stimulator known as Rpf and a genetic test to show which genes the bug is expressing (known as the transcriptome). Because all three indicate the present of non-growing Mtb in sputum and because the levels present varied from patient to patient we wondered whether these 'Fat and Lazy' bacteria were related to the persisters. If this is so, then the numbers of Mtb with these properties in different patients might tell us how quickly they will respond to treatment and, once on therapy, how rapidly the persisters were being eliminated. In preliminary studies we looked at the frequency of fatty Mtb cells in TB patients and related these to how patients responded to treatment. Although numbers were small, we found that patients with higher numbers of fatty Mtb responded more slowly. Then, with colleagues in Liverpool and Malawi, we asked whether counting fatty Mtb cells in sputum samples could tell us which patients were going to fail TB treatment in spite of being infected with an antibiotic sensitive bug. When we compared the levels of fatty Mtb between 9 treatment failures and 29 cured patients we found that the failures had, on average, double the frequency of these 'persister-like' cells. Here we aim to add value to a clinical trial testing a shortened treatment of TB by studying the ability of our tests to predict treatment failure. The RIFASHORT TB treatment trial provides an exceptional opportu
more
|
|
12182
|
Medical research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679776212eaade2e0ee2b8
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007002
|
GCRF_MRC_CO_MR/T022175/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.030722
|
0
|
0
|
0
|
0.030722
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
UNDERSTANDING THE HOME AS A SO...URCE OF INFECTION OF AMR BACTERIA CARRIED BY DUST BY EXPLORING HYGIENE PRACTICES IN DIFFERENT HOME ENVIRONMENTS IN GHANA
more
|
Understanding the home as a so...urce of infection of AMR bacteria carried by dust by exploring hygiene practices in different home environments in Ghana
more
|
AHRC/MRC research grant examin...ing reduction of homebased infections, particularly those carrying antimicrobial resistance, in Ghana. Benefits families with fewer infections and reduces overprescribing antibiotics. SDG 3, 11. Benefits other African LMICs.
more
|
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679776212eaade2e0ee2b9
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020006745
|
GCRF_UKRI_NS_EP/T003642/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.048311
|
0
|
0
|
0
|
0.048311
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
A MULTI-DISCIPLINARY NETWORK O...F SOCIAL SCIENTISTS, POLICY MAKERS, AND CIVIL SOCIETY TO FIGHT TB EPIDEMIC IN THE POST-SOVIET COUNTRIES
more
|
A multi-disciplinary network o...f social scientists, policy makers, and civil society to fight TB epidemic in the Post-Soviet countries
more
|
Tuberculosis remains one of th...e leaders of mortality causes worldwide, despite the fact that the disease is successfully treatable. Post-Soviet countries of Eastern Europe and Central Asia are on the list of high-priority countries for TB control. Exploring other existing networks around TB, we see that they tend to unite the key stakeholder groups among each other - researchers, the civil society or the policy makers with the researchers' network focusing more on medical research and social research around the TB epidemic being not well represented. The proposed unique multidisciplinary network of social scientists (economists, public health researchers, sociologists, epidemiologists, psychologists, criminologists, public communication experts), civil society activists and policy makers will become a platform for ongoing knowledge exchange not only within the groups of stakeholders but across enabling effective adoption of what works best in fighting TB epidemic. This exchange will enable the use of existing research to inform current development of policies and interventions, while establishing a policy-relevant research agenda for the future and reliable venues for dissemination of the results. The key stakeholders of the Network are civil society organizations (representing TB, HIV/AIDS patients, healthcare and public health professionals), policy makers and researchers. The aim of the network is to facilitate the generation of evidence to inform public health policies to reduce the tuberculosis (TB) burden in post-Soviet countries and promote ongoing knowledge exchange among all stakeholders. To achieve this aim, we plan to: 1. Create a platform for network members to promote their existing activities (country case studies, working papers, popular blogs) and collect reference metadata. 2. Hold policy dialogue and networking meetings once a year over 2 days attached to research training meetings for young scholars to allow for them to participate in policy dialogue. The meetings will provide space to share ideas and discuss policies, as well as to develop agenda for the region. 3. Build capacity for early career researchers via the Young Scholar Research Support programme, which is a novel feature of the proposed network. 4. Support TB-relevant research in the Network countries by addressing training needs of the network members and young scholars via webinars and training sessions at the meetings, running of the working paper series and developing methodology for scoping studies and reference metadata We foresee the following outcomes of the Network existence: 1. Developed common TB-focused social research agenda for the region and bespoke agendas for the participating countries, 2. Better understanding of the context nationally, within the region and internationally, 3. Improved local research capacity and policy dialogue, 4. Established collaborations within and across countries (closing the circle of researchers, civil society act
more
|
|
11110
|
Education policy and administr...ative management
more
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679777212eaade2e0ee2ba
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020006749
|
GCRF_UKRI_NS_EP/T003863/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.0485525
|
0
|
0
|
0
|
0.097105
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
50
|
GCRF GLOBAL HEALTH AND CLEAN W...ATER NETWORK
more
|
GCRF Global Health and Clean W...ater Network
more
|
Summary The GCRF Health, Pollu...ted Water and Soils Network of excellence is focused on reducing health problems relating to water and soil pollution in climate-stressed, rural and deprived urban communities in Kenya, Jamaica and Grenada. We aim to achieve this by focusing on affordable and innovative technological and sociological solutions to improve access to clean water, healthy and productive soils and safe, nutritious foods. The network is based on a One Health interdisciplinary, approach, with a growing membership drawn from academic researchers, business leaders, entrepreneurs, health and environmental professionals, government officials, science policy diplomats, community leaders, and civil society and a commitment to grow. Our goal is to build a network of committed individuals, who will work together to solve problems together and will get better at getting things done. Network members will engage in a two-year programme of innovative, interconnected activities, designed to facilitate and enrich the exchange of knowledge, ideas and praxis, build capacity, and help early and mid-career academic participants to connect with the wider community and forge long-lasting, interdisciplinary collaborations and partnerships. The activities include a series 'big-tent' settings including: country-based Knowledge Networks in which entrepreneurs and business will be encouraged to bring new ideas and thinking about social enterprise and for-profit schemes into the network on how to deliver change, Round-tables for diverse groups to 'think out of my box' and develop pathways for realising solutions, on-line Communities of Practice to enable everyone to gain a strong understanding of the issues, evidence and potential solutions through moderated conversations, Workshops and co-laboratories, that will give members and stakeholders the opportunity to co-design innovative ways to improve health through affordable and innovative technological and sociological solutions and improved access to clean water and soils, Demonstration activities and Outreach in local communities to heighten awareness of impacts on health from polluted water and soils and solutions, two Global Digital Conferences which will include on-line presentations, chat groups, interactive sessions, and hackathons, to give network members the opportunity to demonstrate how different issues are being tackled, open access e-learning courses and training webinars on key issues leading to University certification, and an International conference to be held at the Eden Centre, UK to present the outcomes and ideas from the network, consolidate new collaborations and future actions. Some of the measurable outcomes will include improved health in selected communities Grenada, Jamaica and Kenya through greater access to clean water, soils and safe, nutritious foods, lasting partnerships and interdisciplinary collaborations able to exploit opportunities for joint research proposals, business p
more
|
|
43082
|
Research/scientific institutio...ns
more
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679777212eaade2e0ee2bb
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007529
|
GCRF-CRFUKOF-DHF2016-DH150120
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.10879
|
0
|
0
|
0
|
0.10879
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MODELLING THE IMPACT OF GLOBAL... ENVIRONMENTAL CHANGE ON VECTOR-BORNE DISEASE RISK
more
|
Modelling the impact of global... environmental change on vector-borne disease risk
more
|
Fellowship award to develop mo...delling techniques to decipher links between environmental and socio-economic factors on the transmission of climate-sensitive diseases, particularly dengue, chikungunya and Zika viruses. These models enable climate information and forecasts to be integrated into early warning systems to facilitate timely interventions. SDGs 3,13.
more
|
|
12250
|
Infectious disease control
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679777212eaade2e0ee2bc
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020006424
|
GCRF-RFNetG-R6-GCRFNGR6\1073
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.032064
|
0
|
0
|
0
|
0.032064
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
TAPPING THE TAPEWORM TO UNDERS...TAND EPILEPSY: A GLOBAL INITIATIVE.
more
|
Tapping the Tapeworm to Unders...tand Epilepsy: A Global Initiative.
more
|
About five million people in m...any DAC countries suffer from a parasitic infection of the brain caused by the pork tapeworm. The disorder, known as neurocysticercosis is the one of most common causes of epilepsy, a brain disorder manifesting with recurrent seizures. However, we still do not now how often do people with neurocysticercosis have seizures or whether these seizures can be controlled with seizure medicines? We do not know the above because long-term follow-up studies of neurocysticercosis have not been performed. Moreover, manifestations of neurocysticercosis are different in various regions of the world. One of the ways of finding answers to these unresolved questions is to establish a collaborative registry of a large number of cases of neurocysticercosis from different parts of the world and follow-up these over at least five years. We propose networking with international and regional experts in neurocysticercosis from different endemic countries to brainstorm an international collaborative registry project. We will then write a grant proposal to develop the registry. Pooling in data from different countries over a long period of time is likely to yield a wealth of information. By getting all regional experts to partner together, we hope to be able to develop an international network to resolve some of unknown aspects of the parasitic disorder.
more
|
|
43082
|
Research/scientific institutio...ns
more
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679777212eaade2e0ee2bd
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008403
|
MRC_NS_MR/K000950/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.043825
|
0
|
0
|
0
|
0.043825
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
METABOLIC REGULATION OF TISSUE... DESTRUCTION IN TUBERCULOSIS.
more
|
Metabolic regulation of tissue... destruction in tuberculosis.
more
|
MRC CRT fellowship award - Met...abolic regulation of tissue destruction in tuberculosis.
more
|
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679777212eaade2e0ee2be
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008407
|
MRC_NS_MR/R000859/2
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.08172
|
0
|
0
|
0
|
0.08172
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
DISSECTING THE ROLE OF THE LEI...SHMANIA FLAGELLUM IN PATHOGENICITY
more
|
Dissecting the role of the Lei...shmania flagellum in pathogenicity
more
|
MRC IIB award - Dissecting the... role of the Leishmania flagellum in pathogenicity
more
|
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679777212eaade2e0ee2bf
|
2020
|
Germany
|
Foreign Office
|
2020009716
|
6615257
|
8
|
Turkey
|
Europe
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.055288
|
0.055288
|
0
|
0
|
0.055288
|
0.055288
|
|
0.055288
|
|
0
|
Classified as not health-speci...fic activity
more
|
|
100
|
FOOD AID AND COVID-19 PROTECTI...ON PACKAGES DISTRIBUTION PROJECT
more
|
Food Aid and Covid-19 Protecti...on Packages Distribution Project
more
|
Support of vulnerable refugees... and host communities, challenging economic instability and food insecurity through food packages to meet the crises of today and enable them to provide protection against spread of Covid-19
more
|
|
12264
|
COVID-19 control
|
|
I.2.b. Basic Health
|
20000
|
Non-Governmental Organisation ...(NGO) and Civil Society
more
|
Non-governmental organisations... (NGOs) and civil society
more
|
|
COVID-19
|
|
65679778212eaade2e0ee2c0
|
2020
|
United Kingdom
|
Department of Health and Soci...al Care
more
|
2020009717
|
AMR_GC
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
2.432296
|
0
|
0
|
0
|
2.432296
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
ANTIMICROBIAL RESISTANCE IN A ...GLOBAL CONTEXT
more
|
Antimicrobial Resistance in a ...Global Context
more
|
The UK Department of Health an...d Social Care (DHSC) funds outstanding global health research through the National Institute for Health Research (NIHR). This programme is administered by the UK Medical Research Council (MRC), which reports activities under the UK Department for Business, Energy and Industrial Strategy (BEIS). NIHR disburses funds to MRC, which makes onwards disbursements to awardees. This research call supports investments in interdisciplinary and focussed research at international levels to identify the burden and primary drivers of antimicrobial resistance (AMR) and specifically antibacterial resistance in low- and middle-income countries.
more
|
AMR
|
12182
|
Medical research
|
|
|
11004
|
Other public entities in donor... country
more
|
Other public entities in donor... country
more
|
|
|
|
65679778212eaade2e0ee2c1
|
2020
|
Germany
|
Foreign Office
|
2020009718
|
6615263
|
1
|
Zimbabwe
|
South of Sahara
|
Other LICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.011567
|
0.0114565
|
0
|
0
|
0.023134
|
0.022913
|
|
0.023134
|
|
0
|
COVID-19
|
COVID-19 Other
|
50
|
COVID-19 FOOD RELIEF FOR MOST ...AFFECTED HOUSEHOLDS BY LOCKDOWN, AWARENESS AND EDUCATIONAL CAMPAIGNS FOR COMMUNITIES
more
|
Covid-19 Food relief for most ...affected households by lockdown, awareness and educational campaigns for communities
more
|
Alleviation and combatting of ...worst Covid 19 effects like food shortage by distribution of food parcels to the most needy, educational campaigns on prevention of Covid 19 in remote areas
more
|
|
12264
|
COVID-19 control
|
|
I.2.b. Basic Health
|
23000
|
Developing country-based NGO
|
Developing country-based NGO
|
|
COVID-19
|
|
65679778212eaade2e0ee2c2
|
2020
|
Germany
|
Foreign Office
|
2020009713
|
6615256
|
1
|
Turkey
|
Europe
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.01316238
|
0.01263933
|
0
|
0
|
0.039886
|
0.038301
|
|
0.039886
|
|
0
|
COVID-19
|
COVID-19 Personal Protective E...quipment
more
|
33
|
COVID-19 SECURING EDUCATION FO...R YOUNG PEOPLE IN CORONA TIMES
more
|
Covid-19 Securing education fo...r young people in corona times
more
|
Securing education in the Evri...m campus by buying masks, tables and financial support to most vulnerable families for education purposes
more
|
|
11220
|
Primary education
|
|
I.1.b. Basic Education
|
20000
|
Non-Governmental Organisation ...(NGO) and Civil Society
more
|
Non-governmental organisations... (NGOs) and civil society
more
|
|
COVID-19
|
|
65679778212eaade2e0ee2c3
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007017
|
GCRF_MRC_NS_MR/S00016X/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.211002
|
0
|
0
|
0
|
0.211002
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
DEVELOPING A COCKTAIL OF ENZYM...E INHIBITORS TO UNIVERSALLY TREAT HAEMOTOXICITY CAUSED BY SNAKEBITE
more
|
Developing a cocktail of enzym...e inhibitors to universally treat haemotoxicity caused by snakebite
more
|
Background Snakebite is a neg...lected tropical disease that kills ~100,000 people each, year and causes long-term morbidity in 3-5 times that number. Venom variation between snake species severely undermines the efficacy of existing snakebite therapies, known as antivenoms. These intravenously delivered treatments work poorly against bites caused by snake species that were not used to make the antivenom. Therefore many different antivenoms have to be manufactured for each region of the world. In addition, existing antivenoms have (i) poor specificity, (ii) poor safety and (iii) high treatment costs. There is therefore an urgent and compelling need to dramatically improve therapy for the rural impoverished people of the tropics suffering the greatest burden of snakebite. Rationale The most common lethal snakebite pathology is haemotoxicity, which can present clinically as haemorrhage, coagulopathy and/or hypotension, and is primarily caused by three enzymatic venom toxin families. In this project, we seek to develop a new type of therapy for treating haemotoxicity, consisting of repurposed enzyme inhibitors (small molecules). Our preliminary data shows that various enzyme inhibitors are capable of neutralising the enzymatic activity of haemotoxic venom protein families irrespective of the snake species involved, and at lower therapeutic doses than antivenom. We have also demonstrated that inhibitory molecules are capable of preventing snake venom induced lethality in vivo in pre-clinical animal studies. We therefore anticipate that a rationally selected mixture of different enzyme inhibitors will result in a low-dose therapy that (i) neutralises venom lethality irrespective of the snake species, and thus will exert worldwide efficacy, (ii) exhibits a significantly improved safety profile, and (iii) is substantially more affordable than antivenom. Approach We will use a variety of enzyme inhibitors previously approved for human use and test their in vitro and in vivo neutralising capability against ten medically-important, haemotoxic, snake venoms. 1. First, we will use a variety of enzymatic in vitro assays to characterise the haemorrhagic, coagulopathic and hypotensive action of each venom. Subsequently, we will repeat these assays with each venom mixed with individual enzyme inhibitors to identify those inhibitors that confer venom neutralisation. 2. Our preliminary data suggests that combinations of different inhibitors will be required for 'generic' (i.e. across lots of different snake species) neutralisation of venom lethality in vivo, due to the complexity of toxic venom components, and that combinations of enzyme inhibitors can reduce the therapeutic dose required for neutralisation. Consequently, we will repeat our in vitro assays using rational combinations of the different inhibitors identified (those that exhibited neutralising capabilities in 1) at different dose combinations. 3. Lastly, we will demonstrate the superior efficacy of
more
|
NTD
|
12182
|
Medical research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679778212eaade2e0ee2c4
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007033
|
GCRF_UKRI_NS_MR/P027989/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
2.423138
|
0
|
0
|
0
|
2.423138
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
A GLOBAL NETWORK FOR NEGLECTED... TROPICAL DISEASES
more
|
A Global Network for Neglected... Tropical Diseases
more
|
UKRI GROW award - A research n...etwork, spanning the developed and developing world will work on finding new drugs for Chagas Disease and Leishmaniasis. Some 500 researchers at 14 institutes around the world will work to improve on current drugs, some of which are hard to ad
more
|
NTD
|
12250
|
Infectious disease control
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679779212eaade2e0ee2c5
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007000
|
GCRF_MRC_NS_MR/P024661/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.025772
|
0
|
0
|
0
|
0.025772
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
TOWARDS A GLOBAL RESEARCH NETW...ORK FOR THE MOLECULAR PATHOLOGICAL STRATIFICATION OF LEISHMANIASIS.
more
|
Towards a global research netw...ork for the molecular pathological stratification of leishmaniasis.
more
|
The leishmaniasis are parasiti...c diseases caused by one of several species of single cell parasites (Leishmania) that are transmitted to humans by the bite of infected phlebotamine sand flies. These diseases affect over 150 million people across 98 countries worldwide, including many low and middle income countries (LMICs). Some forms of leishmaniasis are fatal, whereas other are very stigmatising and affect quality of life, particularly in children and women. Few drugs are available for patients leishmaniasis and no vaccines are currently registered for use in preventing or treating these diseases. Importantly, the drugs that we do have are not universally effective and often have significant side effects. Sometimes patients even in the same geographical area will respond quite differently to therapy, and for some drugs effectiveness may vary widely between different countries. In order to make the best use of current and future drugs for the leishmaniasis, we need to understand more about why this is the case, and use that information to select appropriate drugs or drug combination for use in different settings. Using the appropriate treatment would save costs in health care, minimise the patient suffering that results from administering ineffective treatments, and reduce the economic burden of disease on patients, their families and communities. In this proposal, we are aiming to lay the foundation blocks that will drive a new way of managing patients with leishmaniasis and conducting research into these diseases. We will use new molecular approaches to extract as much information as possible from small tissue samples that are collected from patients to diagnose their leishmaniasis, and use this information to start to develop new tests that can help clinicians decide on the best course of treatment. We will use the internet to ensure that the information obtained from these tissue samples is used most effectively for research, clinical decision making and for education and training. We will conduct an analysis of the added value of these changes in approach, in order to provide a case for their adoption by health systems in LMICs and by the funders of research. Ultimately, by adopting these practices we will seek to deliver improvements in health and economic prosperity in LMICs. The research we propose over the next two years will not provide all the answers, but will provide necessary proof of concept data to support applications for future funding that may allow us to realise this longer term ambition.
more
|
NTD - Leishmaniasis
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679779212eaade2e0ee2c6
|
2020
|
United Kingdom
|
Department for International D...evelopment
more
|
2019000556b
|
300343-102
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
B03
|
0
|
3.411569
|
0
|
0
|
0
|
3.411569
|
0
|
0
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
WORLD HEALTH ORGANISATION - S...PECIAL PROGRAMME IN RESEARCH AND TRAINING IN TROPICAL DISEASES (TDR) (2018-2022)
more
|
World Health Organisation - S...pecial Programme in Research and Training in Tropical Diseases (TDR) (2018-2022)
more
|
To contribute to research lead...ing to improvements in (i) health systems and policy, (ii) infectious disease knowledge, solutions and implementation of strategies, iii) research to improve sexual and reproductive health
more
|
NTDs
|
12182
|
Medical research
|
|
|
41143
|
World Health Organisation - co...re voluntary contributions account
more
|
World Health Organisation - co...re voluntary contributions account
more
|
|
|
|
65679779212eaade2e0ee2c7
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008277
|
BBSRC_NS_BB/N016165/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.040391
|
0
|
0
|
0
|
0.040391
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
HOW DO COMMON AND DIVERGED FEA...TURES OF THE REPLICATIVE STRESS RESPONSE SHAPE THE BIOLOGY OF TRITRYP PARASITES?
more
|
How do common and diverged fea...tures of the replicative stress response shape the biology of TriTryp parasites?
more
|
Kinetoplastid parasites cause ...pronounced human suffering and economic hardship worldwide. This project will reveal pathways to target the parasites and alleviate the diseases they cause such as sleeping sickness.
more
|
NTDs
|
12182
|
Medical research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679779212eaade2e0ee2c8
|
2020
|
United States
|
Agency for International Devel...opment
more
|
2020008421
|
76_37859
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
3.9
|
3.5
|
0
|
0
|
3.9
|
3.5
|
0
|
3.9
|
|
|
Multilateral
|
GATB
|
100
|
CORE FUNDS TO GLOBAL ALLIANCE ...FOR TB DRUG DEVELOPMENT
more
|
Core funds to Global Alliance ...for TB Drug Development
more
|
Core funds to Global Alliance ...for TB Drug Development
more
|
0
|
12263
|
Tuberculosis control
|
|
I.2.b. Basic Health
|
22000
|
Donor country-based NGO
|
Global Alliance for TB Drug De...velopment
more
|
|
|
|
65679779212eaade2e0ee2c9
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008423
|
MRC_NS_MR/P017339/1
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.748789
|
0
|
0
|
0
|
0.748789
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
GMP MANUFACTURE AND PHASE I CL...INICAL TRIAL OF A THERMOSTABLE SINGLE-DOSE RABIES VACCINE FOR PRE-EXPOSURE PROPHYLAXIS FOR CHILDREN IN ENDEMIC AREAS
more
|
GMP manufacture and Phase I cl...inical trial of a thermostable single-dose rabies vaccine for pre-exposure prophylaxis for children in endemic areas
more
|
MRC BMC: DPFS Full July 2016 a...ward - GMP manufacture and Phase I clinical trial of a thermostable singledose rabies vaccine for preexposure prophylaxis for children in endemic areas
more
|
NTDs
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
